Table 1. Signaling pathways in BON1, H727, HepG2 and Huh7 cells.

Effects of 48h combination treatment with 20 μM lovastatin and 10 nM everolimus after 24h pre-treatment with lovastatin on signaling pathways in BON1, H727, HepG2 and Huh7 cells compared to treatment with each drug separately. Data are shown as mean percentage of the absolute phospho-protein expression, relative to the untreated control, ± SEM.

pEGFR	20 μM lovastatin for 72h	10 nM everolimus for 48h	72h 20 μM lovastatin plus 48h 10 nM everolimus
BON1	77% ± 11%	153% ± 14%	110% ± 25%
H727	55% ± 9%	107% ± 12%	49% ± 10%
HepG2	54% ± 18%	81% ± 20%	53% ± 21%
Huh7	65% ± 13%	93% ± 10%	64% ± 14%
pAKT
BON1	43% ± 6%	74% ± 17%	28% ± 12%
H727	57% ± 16%	190% ± 76%	58% ± 19%
HepG2	55% ± 30%	39% ± 9%	16% ± 4%
Huh7	75% ± 25%	221% ± 25%	152% ± 49%
pERK
BON1	40% ± 11%	88% ± 19%	41% ± 13%
H727	94% ± 15%	85% ± 19%	127% ± 27%
HepG2	60% ± 19%	63% ± 19%	50% ± 14%
Huh7	56% ± 6%	64% ± 6%	62% ± 3%
pp70S6K
BON1	80% ± 11%	16% ± 8%	4% ± 2%
H727	59% ± 17%	22% ± 9%	9% ± 3%
HepG2	598% ± 25%	81% ± 19%	129% ± 23%
Huh7	77% ± 7%	8% ± 4%	1% ± 1%